Commentary on: "Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide".
作者信息
Morrissey K M, Benet L Z, Ware J A
机构信息
Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
出版信息
Clin Transl Sci. 2017 Jul;10(4):240-241. doi: 10.1111/cts.12476. Epub 2017 Jun 29.
Abstract
摘要
相似文献
1
Commentary on: "Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide".关于《OATP1B1功能对索拉非尼-β-D-葡萄糖醛酸苷处置的影响》的评论
Clin Transl Sci. 2017 Jul;10(4):240-241. doi: 10.1111/cts.12476. Epub 2017 Jun 29.
2
Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide.OATP1B1 功能对索拉非尼-β-D-葡糖苷酸处置的影响。
Clin Transl Sci. 2017 Jul;10(4):271-279. doi: 10.1111/cts.12458. Epub 2017 Mar 31.
3
Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1.依折麦布的处置受肝脏摄取载体OATP1B1多态性的影响。
Pharmacogenet Genomics. 2008 Jul;18(7):559-68. doi: 10.1097/FPC.0b013e3282fe9a2c.
4
Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3.洋地黄样化合物与肝脏摄取转运体NTCP、OATP1B1和OATP1B3的相互作用。
Mol Pharm. 2014 Jun 2;11(6):1844-55. doi: 10.1021/mp400699p. Epub 2014 May 6.
5
Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms.有机阴离子转运体OATP1B1（OATP-C）在伊立替康及其活性代谢物7-乙基-10-羟基喜树碱肝脏摄取中的作用：体外证据及单核苷酸多态性的影响
Drug Metab Dispos. 2005 Mar;33(3):434-9. doi: 10.1124/dmd.104.001909. Epub 2004 Dec 17.
6
Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite.小鼠血浆和肝脏匀浆中索拉非尼及索拉非尼葡糖苷酸的液相色谱-串联质谱分析以及葡糖苷酸代谢物的鉴定
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 15;877(3):269-76. doi: 10.1016/j.jchromb.2008.12.026. Epub 2008 Dec 24.
7
Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice.索拉非尼的代谢、转运及肠肝循环：基于生理学的小鼠模型构建与模拟
Cancer Chemother Pharmacol. 2016 May;77(5):1039-52. doi: 10.1007/s00280-016-3018-6. Epub 2016 Apr 6.
8
Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia.评估 UGT1A1、OATP1B1、OATP1B3、MRP2 和 BSEP 的体外抑制作用以预测药物性高胆红素血症。
Mol Pharm. 2013 Aug 5;10(8):3067-75. doi: 10.1021/mp4001348. Epub 2013 Jun 21.
9
Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b.索拉非尼葡糖醛酸的肝细胞穿梭和再循环依赖于Abcc2、Abcc3和Oatp1a/1b。
Cancer Res. 2015 Jul 1;75(13):2729-36. doi: 10.1158/0008-5472.CAN-15-0280. Epub 2015 May 7.
10
The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery.OATP1B1 抑制 assay 的开发、表征和在药物发现中的应用。
Drug Metab Dispos. 2012 Aug;40(8):1641-8. doi: 10.1124/dmd.111.042382. Epub 2012 May 15.
引用本文的文献
1
Uptake Transporters of the SLC21, SLC22A, and SLC15A Families in Anticancer Therapy-Modulators of Cellular Entry or Pharmacokinetics?SLC21、SLC22A和SLC15A家族的摄取转运体在抗癌治疗中——细胞摄取调节剂还是药代动力学调节剂？
Cancers (Basel). 2020 Aug 12;12(8):2263. doi: 10.3390/cancers12082263.
本文引用的文献
1
Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide.OATP1B1 功能对索拉非尼-β-D-葡糖苷酸处置的影响。
Clin Transl Sci. 2017 Jul;10(4):271-279. doi: 10.1111/cts.12458. Epub 2017 Mar 31.
2
Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b.索拉非尼葡糖醛酸的肝细胞穿梭和再循环依赖于Abcc2、Abcc3和Oatp1a/1b。
Cancer Res. 2015 Jul 1;75(13):2729-36. doi: 10.1158/0008-5472.CAN-15-0280. Epub 2015 May 7.
3
Hepatocyte hopping of OATP1B substrates contributes to efficient hepatic detoxification.OATP1B底物的肝细胞跳跃有助于高效的肝脏解毒。
Clin Pharmacol Ther. 2012 Nov;92(5):559-62. doi: 10.1038/clpt.2012.143. Epub 2012 Sep 26.
4
Sorafenib in advanced melanoma: a critical role for pharmacokinetics?索拉非尼治疗晚期黑色素瘤：药代动力学的关键作用？
Br J Cancer. 2012 Jul 24;107(3):455-61. doi: 10.1038/bjc.2012.287. Epub 2012 Jul 5.
5
Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.索拉非尼毒性和暴露随时间的变化：药代动力学/药效学分析。
Oncologist. 2012;17(9):1204-12. doi: 10.1634/theoncologist.2011-0439. Epub 2012 Jul 2.
6
Population pharmacokinetic analysis of sorafenib in patients with solid tumours.索拉非尼治疗实体瘤患者的群体药代动力学分析。
Br J Clin Pharmacol. 2011 Aug;72(2):294-305. doi: 10.1111/j.1365-2125.2011.03963.x.
7
Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters.经摄取转运体和外排转运体协同作用介导的肝胆转运的药代动力学模型。
Drug Metab Rev. 2010 Aug;42(3):539-50. doi: 10.3109/03602530903491824.
8
Predicting in vivo drug interactions from in vitro drug discovery data.从体外药物发现数据预测体内药物相互作用。
Nat Rev Drug Discov. 2005 Oct;4(10):825-33. doi: 10.1038/nrd1851.
9
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.细胞色素P450 3A和P-糖蛋白的重叠底物特异性及组织分布：对癌症化疗中药物递送和活性的影响
Mol Carcinog. 1995 Jul;13(3):129-34. doi: 10.1002/mc.2940130302.
Zotero 插件